Company Overview and News

2
Corium's (CORI) Shares Surge on Merger Agreement With Gurnet

6h zacks
Corium International, Inc. (CORI - Free Report) announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and will also take the company private.
CORI AGN BIIB

36
The October Pause That Refreshes

2018-10-11 seekingalpha
The much-awaited correction is finally here; the question is who will step up to the plate and will actually use it as a long-term buying opportunity.
VRTX AMGN GEC GE BRK.A BIIB GOOGL AAPL CELG GNE MSFT SBUX MS INTC

19
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

2018-10-11 zacks
Teva Pharmaceutical Industries Limited (TEVA - Free Report) along with South Korean partner Celltrion Inc. announced that the FDA’s Oncologic Drugs Advisory Committee has voted unanimously (16-0) recommending approval of CT-P10, their proposed monoclonal antibody (mAb) biosimilar to Roche’s (RHHBY - Free Report) Rituxan.
BIIB TEVJF TEVA NVS TEVVF

12
Novartis Presents Data on Multiple Sclerosis Drug Gilenya

2018-10-11 zacks
Novartis AG (NVS - Free Report) announced encouraging top-line results from the phase IIIb ASSESS study on multiple sclerosis drug, Gilenya.
BIIB NVS MNTA

20
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC

2018-10-11 zacks
Chicago, IL –October 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Altria (MO - Free Report) , U.S. Bancorp (USB - Free Report) ,Biogen (BIIB - Free Report) , Ecolab (ECL - Free Report) and HSBC Holdings (HSBC - Free Report) .
STZ.B STZ HCS USB HSB 0005 BIIB HSEA HSEB URBN HSBC ECL HBCYF

2
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

2018-10-11 globenewswire
CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Through its research initiatives, Biogen Inc. (Nasdaq: BIIB) aims to identify new ways to manage and monitor multiple sclerosis (MS) disease progression and provide physicians with real-world evidence to help inform treatment decisions. Data show serum neurofilament light (sNfL) is a potential biomarker of disease activity and treatment response, and results from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) support the use of technology to broadly monitor for clinically important outcomes, including cognitive changes.
BIIB

7
Top Analyst Reports for Altria, U.S. Bancorp & Biogen

2018-10-10 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), U.S. Bancorp (USB) and Biogen (BIIB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LRCX HD LMT GD SCCO UTX HCS USB HSB 0005 BIIB HSEA HSEB HSBC ECL HBCYF

3
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

2018-10-10 zacks
Roche Holding AG (RHHBY - Free Report) announced that an early treatment with its multiple sclerosis (“MS”) drug Ocrevus significantly reduced disability progression over five years in patients with relapsing MS (“RMS”) and primary progressive MS (“PPMS”). The new data will be presented at the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), scheduled to be held in Berlin, Germany from Oct 10 to 12.
AMGN RHHVF BIIB RHHBY NVS RHHBF

12
Novartis' Applications for MS Drug Accepted by FDA & EMA

2018-10-08 zacks
Novartis AG (NVS - Free Report) announced that both the FDA and the European Medicines Agency (EMA) have accepted the New Drug Application (NDA) and Marketing Authorization Application (MAA), respectively, for pipeline candidate, siponimod (BAF312).
BIIB NVS MNTA

2
Merck signs US$117 mln deal with U.S. government on Samsung Bioepis biosimilar

2018-10-07 english.yonhapnews.co.kr
SEOUL, Oct. 7 (Yonhap) -- Merck, a global health care company, has won a US$117 million contract to supply the biosimilar Renflexis, developed by Samsung Bioepis Co., to the U.S. Department of Veterans Affairs, industry sources said Sunday.
BIIB

2
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

2018-10-06 globenewswire
CAMBRIDGE, Mass., Oct. 06, 2018 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new interim results from NURTURE, an ongoing open-label, single-arm efficacy and safety study of SPINRAZA® (nusinersen) in 25 presymptomatic infants with SMA. The data are being presented today in a late-breaking session at the 23rd Annual Congress of the World Muscle Society (WMS) held in Mendoza, Argentina.
BIIB IONS

3
Alzheon IPO: Wait Until 2019 If You Are Buying Shares

2018-10-05 seekingalpha
Alzheon uses its own platform of molecules for the inhibition of protein misfolding and aggregation to treat Alzheimer's and other neurological illnesses.
BLU BIIB BLUSF NVS ALZH

3
Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam

2018-10-04 zacks
Roche (RHHBY - Free Report) announced interim encouraging clinical data from two pivotal studies — FIREFISH and SUNFISH — on pipeline candidate, risdiplam at the 23rd International Annual Congress of the World Muscle Society in Mendoza, Argentina.
LMT AMGN BIIB NVS PTCT UTX

2
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care

2018-10-02 globenewswire
CAMBRIDGE, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- At the 34th Congress of the European Committee for Treatment and Research in MS in Berlin, Germany (ECTRIMS; 10-12 October), Biogen Inc. (Nasdaq: BIIB) will present data in more than 70 oral and poster presentations on its industry-leading portfolio of multiple sclerosis (MS) products and innovative research efforts aimed at transforming the care of people living with the disease.
BIIB

3
Can Biotech Stocks Power Ahead?

2018-09-29 seekingalpha - 1
Biotech stocks have been on fire this year, and the iShares NASDAQ Biotechnology ETF (IBB) has surged 14.23% on a year-to-date basis. This soundly outperforms the 9.15% gains which have been seen in the S&P 500 (during what is generally thought to be a continued bull market). This strong momentum seen in biotech stocks offers clear advantages for those invested with long positions in the IBB ETF, and strong quarterly earnings in the fund's core components support the outlook in the months ahead.
AMGN GILD BIIB IBB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to BIIB / Biogen Inc. on message board site Silicon Investor.

Biogen Biogen Biogen (BIIB) Biogen Inc. (BIIB) Biogen Inc. (BIIB) Biogen Inc.
CUSIP: 09062X103